Cymabay therapeutics, inc. (CBAY)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Collaboration revenue

-

-

-

-

-

-

-

-

-

5,207

0

0

4,793

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,913

Operating expenses:
Research and development

9,509

20,937

23,193

21,119

18,588

16,397

17,853

14,397

9,477

6,669

4,184

4,044

4,041

3,848

3,534

4,131

4,428

4,051

4,528

4,260

4,187

5,277

3,848

4,083

2,615

1,363

703

969

1,490

2,282

General and administrative

4,347

4,532

4,514

4,529

5,663

4,158

3,276

3,574

3,373

2,894

2,210

3,582

3,701

2,839

2,130

2,215

2,461

1,796

2,201

2,285

2,589

2,332

1,687

1,666

2,500

2,091

683

1,172

925

925

Restructuring charges

100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

13,927

30,544

27,707

25,648

24,251

20,555

21,129

17,971

12,850

9,563

6,394

7,626

7,742

6,687

5,664

6,346

6,889

5,847

6,729

6,545

6,776

7,609

5,535

5,749

5,115

3,454

1,386

2,141

2,415

3,207

Loss from operations

-13,927

-30,544

-27,707

-25,648

-24,251

-20,555

-21,129

-17,971

-12,850

-4,356

-6,394

-7,626

-2,949

-6,687

-5,664

-6,346

-6,889

-5,847

-6,729

-6,545

-6,776

-7,609

-5,535

-5,749

-5,115

-3,454

-1,386

-2,141

-2,415

-294

Other income (expense):
Interest income

839

1,131

1,425

1,610

1,176

1,106

1,113

1,061

708

324

216

44

37

30

45

48

53

61

46

26

27

26

19

17

12

9

-1

1

1

3

Interest expense

-

-

-

-

-

0

0

128

208

234

258

283

305

328

341

336

332

329

265

165

154

191

191

189

184

182

219

209

212

220

Loss on extinguishment of debt

-

-

-

-

-

-

-

-407

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

-

-

-

-

-

0

1,453

-86

-4,655

-777

-1,798

-1,064

-2,134

33

81

-358

320

136

1,083

5,327

4,575

-4,948

-254

2,749

-4,775

-287

298

126

-2

0

Total other income (expense)

839

1,131

1,425

1,610

1,176

1,106

2,566

440

-4,155

-

-1,840

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-13,100

-29,405

-26,282

-24,038

-23,075

-19,449

-18,563

-17,531

-17,005

-5,043

-8,234

-8,929

-5,351

-6,952

-5,879

-6,992

-6,848

-5,979

-5,865

-1,357

-2,328

-12,722

-5,961

-3,172

-10,062

-3,915

-1,307

-2,223

-2,628

-511

Net (loss) income attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

212,228

42,870

-5,367

-5,737

-3,690

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,144

3,109

-

Net loss

-13,100

-29,405

-26,282

-24,038

-23,075

-19,449

-18,563

-17,531

-17,005

-5,043

-8,234

-8,929

-5,351

-6,952

-5,879

-6,992

-6,848

-5,979

-5,865

-1,357

-2,328

-12,722

-5,961

-3,172

-10,062

-3,915

-1,307

-2,223

-2,628

-511

Other comprehensive (loss) income:
Unrealized (loss) gain on marketable securities

-210

-97

-51

183

103

-27

36

65

-88

-31

-12

1

-1

1

3

-4

20

-13

5

-6

7

0

-15

-2

1

-

-

-

-

-2

Total other comprehensive (loss) income

-210

-97

-51

183

103

-27

36

65

-88

-31

-12

1

-1

1

3

-4

20

-13

5

-6

7

0

-15

-2

1

-

-

-

-

-2

Comprehensive loss

-13,298

-29,510

-26,333

-23,855

-22,972

-19,476

-18,527

-17,466

-17,093

-5,074

-8,246

-8,928

-5,352

-6,951

-5,876

-6,996

-6,828

-5,992

-5,860

-1,363

-2,321

-12,722

-5,976

-3,174

-10,061

-804

-1,307

-2,223

-5,737

-513

Basic net loss per common share

-0.19

-0.43

-0.38

-0.35

-0.37

-0.32

-0.31

-0.30

-0.32

-0.07

-0.21

-0.31

-0.20

-0.30

-0.25

-0.30

-0.29

-0.31

-0.27

-0.09

-0.15

-0.87

-0.44

-0.32

-1.02

-

422.95

-917.59

-

-637.05

Diluted net loss per common share

-0.19

-0.43

-0.38

-0.35

-0.37

-0.30

-0.34

-0.30

-0.32

-0.07

-0.21

-0.31

-0.20

-0.30

-0.25

-0.30

-0.29

-0.03

-0.27

-0.09

-0.44

-0.63

-0.44

-0.56

-1.02

-

-1.79

-917.59

-

-637.50

Weighted average common shares outstanding used to calculate basic net loss per common share

68,882

68,842

68,701

68,697

61,890

59,525

59,121

58,833

53,752

44,217

40,035

28,752

26,609

23,447

23,447

23,447

23,447

23,569

21,674

15,258

15,099

14,789

13,468

10,064

9,873

-

101

5

-

5

Weighted average common shares outstanding used to calculate diluted net loss per common share

68,882

68,842

68,701

68,697

61,890

59,306

59,387

58,905

53,752

44,217

40,035

28,752

26,609

23,447

23,447

23,447

23,447

22,992

21,674

15,258

15,743

14,366

13,468

10,487

9,873

-

731

5

-

5

Basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-985.06

-

Weighted average common shares outstanding used to calculate basic and diluted net loss per common share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

-